Sarepta Therapeutics

YTD

ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

CEO

Douglas S. Ingram

CEODouglas S. Ingram

Employees

835

Employees835

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1980

Founded1980

Employees

835

Employees835

SRPT Key Statistics

Market cap

1.75B

Market cap1.75B

Price-Earnings ratio

-1.98

Price-Earnings ratio-1.98

Dividend yield

—

Dividend yield—

Average volume

2.41M

Average volume2.41M

High today

$17.33

High today$17.33

Low today

$16.50

Low today$16.50

Open price

$16.68

Open price$16.68

Volume

2.86M

Volume2.86M

52 Week high

$76.67

52 Week high$76.67

52 Week low

$10.42

52 Week low$10.42

Stock Snapshot

As of today, Sarepta Therapeutics(SRPT) shares are valued at $16.81. The company's market cap stands at 1.75B, with a P/E ratio of -1.98.

During the trading session on 2026-03-22, Sarepta Therapeutics(SRPT) shares reached a daily high of $17.33 and a low of $16.50. At a current price of $16.81, the stock is +1.9% higher than the low and still -3.0% under the high.

Trading volume for Sarepta Therapeutics(SRPT) stock has reached 2.86M, versus its average volume of 2.41M.

The stock's 52-week range extends from a low of $10.42 to a high of $76.67.

SRPT News

Simply Wall St 3d

How Investors Are Reacting To Sarepta Therapeutics Pushing Duchenne Drugs Toward Full FDA Approval

Earlier this week, Sarepta Therapeutics said it plans to file supplemental new drug applications by the end of April to convert the accelerated approvals of its...

TipRanks 3d

Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer

Oppenheimer analyst Andreas Argyrides notes that Sarepta’s (SRPT) management plans to submit an sNDA for Amondys/Vyondys before May 2026. The firm sees the sNDA...

TipRanks 3d

Sarepta provides regulatory update on Amondys 45, Vyondys 53

Sarepta (SRPT) provided an update on its ongoing regulatory interactions with the FDA regarding Amondys 45 and Vyondys 53 for the treatment of Duchenne muscular...

Analyst ratings

52%

of 25 ratings

Buy

28%

Hold

52%

Sell

20%

More SRPT News

Simply Wall St 4d

Has Sarepta Therapeutics Fallen Too Far After A 77% One-Year Share Price Drop?

If you are wondering whether Sarepta Therapeutics at US$16.84 is starting to look mispriced, you are not alone, the stock’s valuation picture is more nuanced th...

TipRanks 6d

Sarepta begins screening, enrollment in Cohort 8 of ENDEAVOR study

Sarepta (SRPT) announced screening and enrollment are underway in Cohort 8 of the ENDEAVOR study. The purpose of Cohort 8 is to assess prophylactic sirolimus tr...

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.